These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2295219)

  • 1. Pharmacokinetics and disposition of the lipid-lowering drug acifran in normal subjects and in patients with renal failure.
    Cayen MN; Ferdinandi ES; Hicks DR; Gonzalez R; Cosyns L; Dubuc J; Kraml M; Edwards KD
    Clin Pharmacol Ther; 1990 Jan; 47(1):50-6. PubMed ID: 2295219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs.
    Cayen MN; Gonzalez R; Ferdinandi ES; Greselin E; Hicks DR; Kraml M; Dvornik D
    Xenobiotica; 1986 Mar; 16(3):251-63. PubMed ID: 3705621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
    Blight AR; Henney HR
    Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disposition of 14C-indapamide in man.
    Klunk LJ; Ringel S; Neiss ES
    J Clin Pharmacol; 1983; 23(8-9):377-84. PubMed ID: 6630587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ranitidine in patients with renal failure.
    Garg DC; Baltodano N; Jallad NS; Perez G; Oster JR; Eshelman FN; Weidler DJ
    J Clin Pharmacol; 1986 Apr; 26(4):286-91. PubMed ID: 3700684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disposition and metabolic fate of 14C-cibenzoline in man.
    Massarella JW; Loh AC; Williams TH; Szuna AJ; Sandor D; Bressler R; Leinweber FJ
    Drug Metab Dispos; 1986; 14(1):59-64. PubMed ID: 2868867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
    Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
    Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolism and disposition of 14C-fenofibrate in human volunteers.
    Weil A; Caldwell J; Strolin-Benedetti M
    Drug Metab Dispos; 1990; 18(1):115-20. PubMed ID: 1970770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renal impairment on the pharmacokinetics of cibenzoline.
    Massarella JW; Khoo KC; Aogaichi K; Di Persio D; Smith M; Kluger J; Chow MS
    Clin Pharmacol Ther; 1988 Mar; 43(3):317-23. PubMed ID: 3345622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transintestinal elimination of ciprofloxacin.
    Rohwedder R; Bergan T; Thorsteinsson SB; Scholl H
    Chemotherapy; 1990; 36(2):77-84. PubMed ID: 2311444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of prazosin.
    Jaillon P
    Clin Pharmacokinet; 1980; 5(4):365-76. PubMed ID: 6994981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
    Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure.
    Rodondi LC; Flaherty JF; Schoenfeld P; Barriere SL; Gambertoglio JG
    Clin Pharmacol Ther; 1989 May; 45(5):527-34. PubMed ID: 2721108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transintestinal elimination of ciprofloxacin.
    Rohwedder RW; Bergan T; Thorsteinsson SB; Scholl H
    Diagn Microbiol Infect Dis; 1990; 13(2):127-33. PubMed ID: 2369809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function.
    Mahon WA; Johnson GE; Endrenyl L; Kelly MF; Fenton SS
    Scand J Infect Dis Suppl; 1976; (9):24-31. PubMed ID: 1070145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.